102 related articles for article (PubMed ID: 27467088)
1. In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis.
Przybylak KR; Cronin MT
Mol Inform; 2011 May; 30(5):415-29. PubMed ID: 27467088
[TBL] [Abstract][Full Text] [Related]
2. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
Orogo AM; Choi SS; Minnier BL; Kruhlak NL
Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
[TBL] [Abstract][Full Text] [Related]
3. How does the quality of phospholipidosis data influence the predictivity of structural alerts?
Przybylak KR; Alzahrani AR; Cronin MT
J Chem Inf Model; 2014 Aug; 54(8):2224-32. PubMed ID: 25062434
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach.
Goracci L; Buratta S; Urbanelli L; Ferrara G; Di Guida R; Emiliani C; Cross S
Eur J Med Chem; 2015 Mar; 92():49-63. PubMed ID: 25544686
[TBL] [Abstract][Full Text] [Related]
5. Establishment of an in silico phospholipidosis prediction method using descriptors related to molecular interactions causing phospholipid-compound complex formation.
Haranosono Y; Nemoto S; Kurata M; Sakaki H
J Toxicol Sci; 2016 Apr; 41(2):321-8. PubMed ID: 26961617
[TBL] [Abstract][Full Text] [Related]
6. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
7. pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery.
Balogh GT; Müller J; Könczöl A
Eur J Pharm Sci; 2013 Apr; 49(1):81-9. PubMed ID: 23439241
[TBL] [Abstract][Full Text] [Related]
8. Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M; Tripal P; Roas F; Kornhuber J
ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
[TBL] [Abstract][Full Text] [Related]
9. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
Almela MJ; Torres PA; Lozano S; Herreros E
Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
[TBL] [Abstract][Full Text] [Related]
11. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
12. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
13. Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints.
Slavov SH; Wilkes JG; Buzatu DA; Kruhlak NL; Willard JM; Hanig JP; Beger RD
Bioorg Med Chem; 2014 Dec; 22(23):6706-6714. PubMed ID: 25228124
[TBL] [Abstract][Full Text] [Related]
14. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
[TBL] [Abstract][Full Text] [Related]
15. Modeling phospholipidosis induction: reliability and warnings.
Goracci L; Ceccarelli M; Bonelli D; Cruciani G
J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521
[TBL] [Abstract][Full Text] [Related]
16. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
17. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis.
Kuroda Y; Saito M
Toxicol In Vitro; 2010 Mar; 24(2):661-8. PubMed ID: 19786086
[TBL] [Abstract][Full Text] [Related]
18. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA
Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356
[TBL] [Abstract][Full Text] [Related]
20. AMALPHI: A Machine Learning Platform for Predicting Drug-Induced PhospholIpidosis.
Lomuscio MC; Abate C; Alberga D; Laghezza A; Corriero N; Colabufo NA; Saviano M; Delre P; Mangiatordi GF
Mol Pharm; 2024 Feb; 21(2):864-872. PubMed ID: 38134445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
